The case for & against
Bull & Bear analysis
Bearish
TherapeuticsMD, Inc. (NASDAQ: TXMD) is a healthcare company focused on women's health, dedicated to developing and commercializing innovative products that address unmet medical needs for women. This includes therapies related to contraception and menopause management. Maintaining a competitive edge in the women's healthcare market, TherapeuticsMD operates in a theme that highlights the rising demand for personalized healthcare solutions. This momentum is supported by strategic partnerships and a focus on optimizing access to their products across various healthcare channels.
Bull says
- ↑24% YoY net revenue increase to $28.6M, Anvera sales up 91%.
- ↑Divested VitaCare for $142.6M, used $120M to cut debt.
- ↑Expanded Anavera prescribers by 1,487 to over 12,000 total.
- ↑Unique long-lasting, patient-controlled contraceptive offering vs competitors.
- ↑Management forecasts manufacturing improvements to sustain production.
- ↑Attractive book-to-price ratio (1.25) with positive growth and analyst revisions.
Bear says
- ↓Manufacturing issues cut net revenue from $19.9M to $19.3M YoY.
- ↓Operating expenses rose 21% to $42.7M, cash burn $29.5M.
- ↓Negative earnings yield and weak profitability raise income concerns.
- ↓FDA manufacturing-spec decision pending, stalling full-year guidance.
- ↓Competitive pricing pressure trimmed Invexi sales by 32.2%.
- ↓Low dividend yield and potential price volatility limit appeal.
Earnings Call · Q2 2021 · Mgmt. Guidance
Updated 07-04-2026bullish
Transcript signals
Bull points
- We are pleased with our steady progress in line with our expectations.
- Our sales force is benefiting from improved access to providers, which while not back to pre-pandemic levels, has opened up.
- In addition, the efforts we have made during the quarter to create a more streamlined and improved online patient experience are gaining traction.
Bear points
- Operating expenses increased in the second quarter as we had anticipated, reflecting our continued investment to enhance marketing and strengthen our digital capabilities. As a result of this investment, we expect the expenses in the back half of the year to be moderately higher than the first half of the year.
- Net cash used in operating activities was $26.5 million for the second quarter.
- Turning to Byjuva, net revenue decreased by 12%, and average net revenue per unit was $68. As a reminder, we are minimally supporting Byjuva at present.
Read full transcript analysis ›